Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Regulation of Angiogenesis and Blood Supply

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Psychological Outcomes After Hypospadias Repair: Does Age at Surgery Matter? A Systematic Review.

Cureus·2026

Same author

Correction: Psychological Outcomes After Hypospadias Repair: Does Age at Surgery Matter? A Systematic Review.

Cureus·2026

Same author

Long-term renal outcomes in children with posterior urethral valves: a systematic review and meta-analysis.

Pediatric surgery international·2026

Same author

Non-operative management of early onset small urethrocutaneous fistula post hypospadias repair: a systematic review.

World journal of urology·2026

Same author

Growth Differentiation Factor-15 Could Predict Decreased Hemoglobin in Tuberculosis Treated With Linezolid-Containing Regimen.

The clinical respiratory journal·2026

Same author

The usage of ureteral catheter outside of the ureteral access sheath to facilitate stone passage through the UAS during RIRS: A case report.

Urology case reports·2026

Search research articles

Related Experiment Video

Updated: May 13, 2025

Mouse Bladder Wall Injection

Mouse Bladder Wall Injection

Published on: July 12, 2011

Molecular Dynamic Stability Study of VEGF Inhibitor in Patients with Bladder Cancer.

Ginanda Putra Siregar¹, Ida Parwati¹, Tjahjodjati Tjahjodjati¹

¹Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.

Acta Informatica Medica : AIM : Journal of the Society for Medical Informatics of Bosnia & Herzegovina : Casopis Drustva Za Medicinsku Informatiku Bih

|April 14, 2025

Summary

Brolucizumab shows potential as a bladder cancer therapeutic by strongly inhibiting vascular endothelial growth factor receptor 2 (VEGFR2). Molecular simulations reveal its effective binding and blocking action against VEGFR2, crucial for cancer growth.

Keywords:

Brolucizumab bladder neoplasms molecular docking simulation vascular endothelial growth factor

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Related Experiment Videos

Last Updated: May 13, 2025

Mouse Bladder Wall Injection

Mouse Bladder Wall Injection

Published on: July 12, 2011

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Vascular endothelial growth factor (VEGF) is vital for bladder cancer progression.
Brolucizumab, an anti-VEGF agent, has potential therapeutic applications in bladder cancer, though largely unexplored.

Purpose of the Study:

To investigate the molecular docking and dynamic stability of Brolucizumab as a VEGF inhibitor in bladder cancer.
To analyze Brolucizumab's interaction with VEGFA and VEGFR2 at a molecular level.

Main Methods:

Utilized molecular docking and dynamic simulations (Discovery Studio, Pyrx, HADDOCK, YASARA).
Performed protein-ligand and protein-protein docking to assess binding interactions.
Analyzed conformational changes and binding affinities.

Main Results:

Brolucizumab binding induced distinct conformational changes in VEGFR2, indicating an inhibitory effect.
Brolucizumab demonstrated strong, competitive binding to VEGFA with higher affinity than VEGFR2.
Observed bond relaxation and conformational shifts upon Brolucizumab binding to VEGFA and VEGFR2.

Conclusions:

Brolucizumab exhibits significant inhibitory and blocking activity against VEGFR2.
Brolucizumab shows promise as a potential therapeutic agent for bladder cancer treatment.